| 日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
| 2024/05/08 | 17 : 46 | Alliance News |  MaxCyte shares rise amid double-digit revenue increase | LSE:MXCT | Maxcyte Inc |
| 2024/05/08 | 15 : 05 | RNS Regulatory News | MaxCyte, Inc. Filing of Form 10-Q | LSE:MXCT | Maxcyte Inc |
| 2024/05/08 | 15 : 00 | RNS Regulatory News | MaxCyte, Inc. First Quarter Results | LSE:MXCT | Maxcyte Inc |
| 2024/05/03 | 15 : 00 | RNS Regulatory News | MaxCyte, Inc. Notice of AGM | LSE:MXCT | Maxcyte Inc |
| 2024/05/02 | 01 : 04 | RNS Regulatory News | MaxCyte, Inc. Total Voting Rights | LSE:MXCT | Maxcyte Inc |
| 2024/04/10 | 21 : 05 | RNS Regulatory News | MaxCyte, Inc. Notice of Results | LSE:MXCT | Maxcyte Inc |
| 2024/04/03 | 15 : 00 | RNS Regulatory News | MaxCyte, Inc. Total Voting Rights and Block Listing Return | LSE:MXCT | Maxcyte Inc |
| 2024/04/02 | 23 : 19 | Alliance News | TRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian firms farmout | LSE:MXCT | Maxcyte Inc |
| 2024/04/02 | 21 : 05 | RNS Regulatory News | MaxCyte, Inc. Signing of Strategic Platform License | LSE:MXCT | Maxcyte Inc |
| 2024/04/02 | 15 : 00 | RNS Regulatory News | MaxCyte, Inc. Exercise of options and PDMR dealing | LSE:MXCT | Maxcyte Inc |
| 2024/03/20 | 19 : 16 | RNS Regulatory News | MaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR Dealing | LSE:MXCT | Maxcyte Inc |
| 2024/03/20 | 19 : 05 | RNS Regulatory News | MaxCyte, Inc. Grant of Options, RSUs and PSUs and PDMR Dealing | LSE:MXCT | Maxcyte Inc |
| 2024/03/13 | 20 : 54 | Alliance News | IN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25% | LSE:MXCT | Maxcyte Inc |
| 2024/03/13 | 16 : 05 | RNS Regulatory News | MaxCyte, Inc. Filing of form 10-K for FY ended December 31, 2023 | LSE:MXCT | Maxcyte Inc |
| 2024/03/13 | 16 : 00 | RNS Regulatory News | MaxCyte, Inc. Reports Q4 & FY 2023 Financial Results | LSE:MXCT | Maxcyte Inc |
| 2024/03/13 | 05 : 05 | UK Regulatory | MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance | LSE:MXCT | Maxcyte Inc |
| 2024/03/06 | 17 : 58 | RNS Regulatory News | MaxCyte, Inc. TR-1: Notification of major holdings | LSE:MXCT | Maxcyte Inc |
| 2024/03/06 | 05 : 43 | Alliance News | EARNINGS: dotdigital eyes rosy future; Beeks Financial turns to profit | LSE:MXCT | Maxcyte Inc |
| 2024/03/05 | 16 : 00 | RNS Regulatory News | MaxCyte, Inc. Preliminary FY Results & 2024 Guidance | LSE:MXCT | Maxcyte Inc |
| 2024/03/05 | 06 : 05 | UK Regulatory | MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results | LSE:MXCT | Maxcyte Inc |
| 2024/03/02 | 02 : 57 | RNS Regulatory News | MaxCyte, Inc. Total Voting Rights | LSE:MXCT | Maxcyte Inc |
| 2024/02/29 | 18 : 21 | RNS Regulatory News | MaxCyte, Inc. Exercise of options and PDMR dealing | LSE:MXCT | Maxcyte Inc |
| 2024/02/26 | 16 : 00 | RNS Regulatory News | MaxCyte, Inc. TR-1: Notification of major holdings | LSE:MXCT | Maxcyte Inc |
| 2024/02/09 | 22 : 05 | RNS Regulatory News | MaxCyte, Inc. Notice of Results | LSE:MXCT | Maxcyte Inc |
| 2024/02/09 | 22 : 05 | UK Regulatory | MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences | LSE:MXCT | Maxcyte Inc |
| 2024/02/01 | 18 : 24 | RNS Regulatory News | MaxCyte, Inc. Total Voting Rights | LSE:MXCT | Maxcyte Inc |
| 2024/01/31 | 16 : 00 | RNS Regulatory News | MaxCyte, Inc. Director/PDMR Shareholding | LSE:MXCT | Maxcyte Inc |
| 2024/01/30 | 23 : 29 | RNS Regulatory News | MaxCyte, Inc. Holding(s) in Company | LSE:MXCT | Maxcyte Inc |
| 2024/01/30 | 22 : 58 | Alliance News | IN BRIEF: MaxCyte signs licencing deal with cell therapy company Wugen | LSE:MXCT | Maxcyte Inc |
| 2024/01/30 | 22 : 05 | UK Regulatory | MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers | LSE:MXCT | Maxcyte Inc |